

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-69. (Cancelled)

70-95. (Cancelled)

96. (Currently Amended) A polynucleotide encoding a heavy chain or a variable heavy chain region of ~~an~~ a monoclonal antibody that specifically binds human IL-13, wherein said antibody comprises antigen-binding regions derived from an anti-IL-13 antibody comprising the amino acid sequence of an antibody produced by a hybridoma designated with American Type Culture Collection ("ATCC") accession number PTA-5657.

97. (Currently Amended) A polynucleotide encoding a light chain or a variable light chain region of ~~an~~ a monoclonal antibody that specifically binds human IL-13, wherein said antibody comprises antigen-binding regions derived from an anti-IL-13 antibody comprising the amino acid sequence of an antibody produced by a hybridoma designated with ATCC accession number PTA-5657.

98. (Previously Presented) The polynucleotide of claim 96, wherein said antibody that binds human IL-13 comprises (i) complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and (ii) complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

99. (Currently Amended) The polynucleotide of claim 97, wherein said antibody that binds human IL-13 comprises ~~(ii)~~ (i) complementarity determining regions CDRH1, CDRH2 and

CDRH3 having the amino acid sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and (ii) complementarity determining regions CDRL1, CDRL2 and CDRL3 having the amino acid sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

100. (Previously Presented) The polynucleotide of claim 96, wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143.

101. (Previously Presented) The polynucleotide of claim 97, wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 142.

102. (Currently Amended) ~~The polynucleotide of claim 96~~ A polynucleotide encoding a heavy chain or a variable heavy chain region of a monoclonal antibody that specifically binds human IL-13, wherein said antibody ~~that binds human IL-13~~ comprises:

(1) a CDRH1 having the amino acid sequence of SEQ ID NO: 117 or SEQ ID NO: 117 consisting of one amino acid substitution resulting in the amino acid sequence of SEQ ID NO: 117, 118, 119, 120, 121 or 122;

(2) a CDRH2 having the amino acid sequence of SEQ ID NO: 123 or SEQ ID NO: 123 consisting of one amino acid substitution resulting in the amino acid sequence of SEQ ID NO: 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133 or 134; and

(3) a CDRH3 having the amino acid sequence of SEQ ID NO: 135 or SEQ ID NO: 135 consisting of one or two amino acid substitutions resulting in the amino acid sequence of SEQ ID NO: 135, 136, 137, 138, 139, 140 or 141.

103. (Currently Amended) ~~The polynucleotide of claim 97~~ A polynucleotide encoding a light chain or a variable light chain region of a monoclonal antibody that specifically binds human IL-13, wherein said antibody ~~that binds human IL-13~~ comprises:

(1) a CDRL1 having the amino acid sequence of SEQ ID NO: 99 or SEQ ID NO: 99
consisting of one or two amino acid substitutions resulting in the amino acid sequence of SEQ ID
NO: 99, 100, 101, 102, or 103;

(2) a CDRL2 having the amino acid sequence of SEQ ID NO: 104 or SEQ ID NO: 104
consisting of one amino acid substitution resulting in the amino acid sequence of SEQ ID NO:
104, 105, 106, 107, 108, 109, 110, 111, 112, 113, or 114; and

(3) a CDRL3 having the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 115
consisting of one amino acid substitution resulting in the amino acid sequence of SEQ ID NO:
115 or 116.

104. (Previously Presented) The polynucleotide of claim 96, wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 4, 143, 145, 146, 147, 148 or 149.

105. (Previously Presented) The polynucleotide of claim 97, wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 3, 142, 144 or 150.

106. (Currently Amended) The polynucleotide of claim 96 or 98, wherein said antibody that binds human IL-13 is ~~selected from the group consisting of:~~ a monovalent antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a Fab fragment, ~~and~~ or a F(ab') fragment.

107. (Currently Amended) The polynucleotide of claim 97 or 99, wherein said antibody that binds human IL-13 is ~~selected from the group consisting of:~~ a monovalent antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a Fab fragment, ~~and~~ or a F(ab') fragment.

108. (Cancelled)

109. (Cancelled)

110. (Previously Presented) The polynucleotide of claim 104, wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 4.

111. (Previously Presented) The polynucleotide of claim 105, wherein said antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 3.

112. (Previously Presented) The polynucleotide of claim 106, wherein the antibody is a multispecific antibody that is a bispecific antibody.

113. (Previously Presented) The polynucleotide of claim 107, wherein the antibody is a multispecific antibody that is a bispecific antibody.

114. (Previously Presented) The polynucleotide of claim 106, wherein the antibody is a humanized antibody.

115. (Previously Presented) The polynucleotide of claim 107, wherein the antibody is a humanized antibody.

116. (Currently Amended) A polynucleotide encoding a heavy chain or a variable heavy chain region of ~~an~~ a monoclonal antibody that specifically binds human IL-13, wherein said antibody is a humanized antibody of an antibody produced by a hybridoma designated with ATCC accession number PTA-5657.

117. (Currently Amended) A polynucleotide encoding a light chain or a variable light chain region of ~~an~~ a monoclonal antibody that specifically binds human IL-13, wherein said antibody is a humanized antibody of an antibody produced by a hybridoma designated with ATCC accession number PTA-5657.

118. (Previously Presented) A polynucleotide encoding a heavy chain or a variable heavy chain region of an antibody that binds human IL-13, wherein said antibody comprises a

variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

119. (Previously Presented) A polynucleotide encoding a light chain or a variable light chain region of an antibody that binds human IL-13, wherein said antibody comprises a variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

120. (Previously Presented) The polynucleotide of claim 116, wherein said antibody that binds human IL-13 comprises a variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

121. (Previously Presented) The polynucleotide of claim 117, wherein said antibody that binds human IL-13 comprises a variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a

variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively.

122. (Previously Presented) The polynucleotide of claim 116, wherein the antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143 and SEQ ID NO: 142.

123. (Previously Presented) The polynucleotide of claim 117, wherein the antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143 and SEQ ID NO: 142.

124. (Previously Presented) The polynucleotide of claim 118, wherein the antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143 and SEQ ID NO: 142.

125. (Previously Presented) The polynucleotide of claim 119, wherein the antibody that binds human IL-13 comprises the amino acid sequence of SEQ ID NO: 143 and SEQ ID NO: 142.

126. (Previously Presented) The polynucleotide of claim 116, 117, 120, or 121, wherein said antibody that binds human IL-13 is selected from the group consisting of: a monovalent antibody, a multispecific antibody, a single chain antibody, a Fab fragment, and a F(ab') fragment.

127. (Previously Presented) The polynucleotide of claim 126, wherein said antibody that binds human IL-13 is a multispecific antibody that is a bispecific antibody.

128. (Cancelled)

129. (Currently Amended) The polynucleotide of claim 118, or 119, wherein said antibody that binds human IL-13 is ~~selected from the group consisting of:~~ a monovalent antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a Fab fragment, ~~and~~ or a F(ab') fragment.

130. (Previously Presented) The polynucleotide of claim 129, wherein said antibody that binds human IL-13 is a multispecific antibody that is a bispecific antibody.

131. (Previously Presented) The polynucleotide of claim 118 or 119, wherein said antibody is a monoclonal antibody.

132. (Previously Presented) The polynucleotide of claim 116, 117, 120, or 121, wherein the antibody is an IgG antibody.

133. (Previously Presented) The polynucleotide of claim 118 or 119, wherein the antibody is an IgG antibody.

134. (Previously Presented) The polynucleotide of claim 132, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.

135. (Previously Presented) The polynucleotide of claim 133, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.

136. (Previously Presented) The polynucleotide of claim 96, 97, 98, or 99, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.

137. (Previously Presented) The polynucleotide of claim 136, wherein the antibody is an IgG1, an IgG2, an IgG3 or an IgG4 antibody.

138. (Currently Amended) A vector comprising one or more of the polynucleotide of claim 116, 117, ~~118~~ 118, or 119.

139. (Previously Presented) The vector of claim 138, wherein said vector comprises a polynucleotide encoding (i) a heavy chain or a variable heavy chain region, and (ii) a light chain or a variable light chain region, of the antibody that binds human IL-13.

140. (Previously Presented) A host cell comprising one or more vectors of claim 138.

141. (Previously Presented) A host cell comprising a vector of claim 139.

142. (Previously Presented) The host cell of claim 140, wherein the host cell is a mammalian cell.

143. (Previously Presented) The host cell of claim 141, wherein the host cell is a mammalian cell.

144. (Previously Presented) The host cell of claim 142, wherein the mammalian cell is a Chinese hamster ovary (CHO) cell.

145. (Previously Presented) The host cell of claim 143, wherein the mammalian cell is a Chinese hamster ovary (CHO) cell.

146. (Previously Presented) The host cell of claim 140, wherein the host cell is a bacteria.

147. (Previously Presented) The host cell of claim 141, wherein the host cell is a bacteria.

148. (Previously Presented) A method of producing an antibody that binds human IL-13, wherein said method comprises culturing a host cell of claim 140.

149. (Previously Presented) A method of producing an antibody that binds human IL-13, wherein said method comprises culturing a host cell of claim 141.

150. (Previously Presented) A method of producing an antibody that binds human IL-13, wherein said method comprises culturing a host cell of claim 142.

151. (Previously Presented) A method of producing an antibody that binds human IL-13, wherein said method comprises culturing a host cell of claim 143.

152. (Previously Presented) The method claim 148, further comprising the step of obtaining the antibody expressed by the host cell.

153. (Previously Presented) The method claim 149, further comprising the step of obtaining the antibody expressed by the host cell.

154. (Previously Presented) The method claim 150, further comprising the step of obtaining the antibody expressed by the host cell.

155. (Previously Presented) The method claim 151, further comprising the step of obtaining the antibody expressed by the host cell.